15 results
10-K
2020 FY
BOLT
Bolt Biotherapeutics Inc
31 Mar 21
Annual report
4:06pm
on the lives of patients, they also have several shortcomings and limitations:
T cell exhaustion: Due to chronic antigen stimulation, activated T … for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union
424B4
BOLT
Bolt Biotherapeutics Inc
5 Feb 21
Prospectus supplement with pricing info
4:44pm
:
T cell exhaustion: Due to chronic antigen stimulation, activated T cells become less effective over time, losing much of their function due … , prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives
S-1/A
uofrspn
1 Feb 21
IPO registration (amended)
6:24am
S-1
EX-10.17
k4ptn
15 Jan 21
IPO registration
3:58pm
S-1
nb7esm18n9jbiiox
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.18
iootcc2p4ib0lddgr57t
15 Jan 21
IPO registration
3:58pm
DRS/A
2mtp9b nzn7684udp
11 Jan 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.18
1bfsg ffjx3
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.17
5f8y2jrndotkkpw0tc
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
fy9 jw3971k
11 Sep 20
Draft registration statement (amended)
12:00am
DRS
rbu7fxnkw06a h2gaozl
10 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next